

TO: *Don Kennedy*  
SEP 26 1980

*Whitehead Institute*

*- personal*

The visit with you + Ken last month was certainly very productive.

You should know that David Baltimore is far and away the front runner as director - apparent, and he will have a major role in further choices and discussions. My assay of site preferences at this time - and this is subject to modulation by other aspects of a concordat - is:

	<i>Jacks</i>	<i>Dave</i>	<i>(SL: re scientific utility)</i>
Stanford	2	2	1
MIT	3	1	3
R.U.	1	3	2

We (R.U.) will, I am sure, make some offer to Jacks + Dave that will at least roughly match what we discussed for

TO:

Stanford. But the different valuation of real estate makes it hard to generate a symmetrical perspective. Obviously much hinges on what Dave can get from MIT that would match his preferences. But I think he would seriously consider alternatives if that doesn't work out.

So don't let this get to be torpedoed at Stanford - for the wrong reasons - as happened last time.

The important goal is to be sure that \$150M+ does come to biomedical research, no matter where.

*Yours,*



Joshua Lederberg  
President  
The Rockefeller University  
New York, N.Y. 10021  
(212) 360-1234

☐ ORIG.  
☐ COPY

RETAILED  
- REPLY FORM -

*CC: Ken Melmon*

Joshua Lederberg  
President  
The Rockefeller University  
New York, N.Y. 10021  
(212) 360-1234

☐ ORIG.  
☐ COPY

RETAILED  
- REPLY FORM -